News articles about PDL BioPharma (NASDAQ:PDLI) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PDL BioPharma earned a news impact score of 0.19 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 48.8005934626157 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

PDLI traded down $0.09 during midday trading on Monday, hitting $2.36. 57,712 shares of the company’s stock traded hands, compared to its average volume of 1,249,965. The firm has a market cap of $356.23 million, a PE ratio of 3.73 and a beta of 0.30. The company has a debt-to-equity ratio of 0.17, a quick ratio of 10.80 and a current ratio of 11.13. PDL BioPharma has a one year low of $2.27 and a one year high of $3.55.

PDL BioPharma (NASDAQ:PDLI) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.04. The firm had revenue of $46.58 million for the quarter. PDL BioPharma had a negative net margin of 31.33% and a positive return on equity of 8.92%. sell-side analysts anticipate that PDL BioPharma will post -0.6 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on PDLI shares. Cowen reissued a “hold” rating and issued a $2.50 price target on shares of PDL BioPharma in a research report on Thursday, June 14th. Zacks Investment Research raised shares of PDL BioPharma from a “sell” rating to a “hold” rating in a research report on Tuesday, June 19th. BidaskClub lowered shares of PDL BioPharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 20th. TheStreet lowered shares of PDL BioPharma from a “c-” rating to a “d+” rating in a research report on Friday, August 17th. Finally, ValuEngine lowered shares of PDL BioPharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 23rd. Two investment analysts have rated the stock with a sell rating and two have given a hold rating to the company. The company has an average rating of “Hold” and a consensus price target of $3.00.

About PDL BioPharma

PDL BioPharma, Inc acquires and manages companies, products, royalty agreements, and debt facilities in the biotechnology, pharmaceutical, and medical device industries in the United States, Europe, and internationally. The company operates in three segments: Income Generating Assets, Pharmaceutical, and Medical Devices.

Recommended Story: Average Daily Trade Volume – What You Need to Know

Insider Buying and Selling by Quarter for PDL BioPharma (NASDAQ:PDLI)

Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with's FREE daily email newsletter.